Online Course
on demand
01
Mar
2021
05
Mar
2021
Molecular Diagnostics and Genomics in Breast Cancer

Chairs: M.S. Aapro, CH  - J. Gligorov, FR

BACKGROUND
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.

LEARNING OBJECTIVES
  • Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
  • Practicing through case discussions

CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certficate that will be issued by email. 
Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 8 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.

ACKNOWLEDGEMENTS
Sharing Progress in Cancer Care wishes to extend its appreciation to Daiichi Sankyo, Exact Sciences and Pfizer for having granted their participation and support to the Course.
01/03/2021 15:45 CET

Welcome and introduction

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
01/03/2021 15:50 CET

Optimize patient management in breast cancer: guiding adjuvant treatment decisions/

Expert: Verrill Mark, UK
01/03/2021 16:05 CET

Clinical utility of multigene assays in early breast cancer

01/03/2021 16:25 CET

Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions)

01/03/2021 17:05 CET

Discussion and Q&A

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
Expert: Batistatou Anna, GR
Expert: Cognetti Francesco, IT
Expert: Markopoulos Christos, GR
Expert: Nitz Ulrike, DE
Expert: Verrill Mark, UK
02/03/2021 15:45 CET

Welcome and introduction

02/03/2021 15:50 CET

Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…?

02/03/2021 16:20 CET

The essential pathology testing needed for breast cancer, quality control

Expert: Batistatou Anna, GR
02/03/2021 16:40 CET

What tests to ask for and what clinical implications in "TRIPLE NEGATIVE" BrCa”

Expert: Harbeck Nadia, DE
02/03/2021 16:55 CET

The patient advocacy perspective

Expert: Zambon Marzia, IT
02/03/2021 17:25 CET

Discussion and Q&A

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
Expert: Batistatou Anna, GR
Expert: Harbeck Nadia, DE
Expert: Nitz Ulrike, DE
Expert: Pujol Pascal, FR
Expert: Verrill Mark, UK
Expert: Zambon Marzia, IT
03/03/2021 17:20 CET

Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results?

Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk
Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk
Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk
Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk
03/03/2021 17:20 CET

Group 1

Expert: Gligorov Joseph, FR
Expert: Masetti Riccardo, IT
Expert: Senkus Elzbieta, PL
Expert: Varga Zsuzsanna , CH
03/03/2021 17:20 CET

Group 2

Expert: Aapro Matti, CH
Expert: Markopoulos Christos, GR
Expert: Martin Miguel, ES
Expert: Pruneri Giancarlo, IT
03/03/2021 18:40 CET

Panellists case discussion summary and Q&A

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
Expert: Markopoulos Christos, GR
Expert: Masetti Riccardo, IT
Expert: Nitz Ulrike, DE
Expert: Pruneri Giancarlo, IT
Expert: Senkus Elzbieta, PL
Expert: Varga Zsuzsanna , CH
04/03/2021 15:45 CET

Advanced breast cancer (PART 1) - Welcome and introduction

04/03/2021 15:50 CET

DNA Methylation

Expert: Danesi Romano, IT
04/03/2021 16:10 CET

NGS impact or not in breast cancer

Expert: André Fabrice, FR
04/03/2021 16:30 CET

Alpelisib what to test

04/03/2021 17:15 CET

Discussion and Q&A

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
Expert: André Fabrice, FR
Expert: Danesi Romano, IT
Expert: Penault-Llorca Frederique, FR
Expert: Senkus Elzbieta, PL
05/03/2021 15:45 CET

Advanced breast cancer (PART 2) - Welcome and introduction

05/03/2021 15:50 CET

Parp inhibitors what to test

05/03/2021 16:20 CET

Immunotherapy: what to test

05/03/2021 16:50 CET

HER-2 alterations not defined as ASCO CAP HER-2 positivity

05/03/2021 17:35 CET

Discussion, Q&A and Closure

Chair: Aapro Matti, CH
Chair: Gligorov Joseph, FR
Expert: Cognetti Francesco, IT
Expert: Nitz Ulrike, DE
Expert: Penault-Llorca Frederique, FR
Expert: Pujol Pascal, FR
Aapro Matti

Sharing Progress in Cancer Care and Clinique de Genolier, Bellinzona and Genolier, Switzerland
André Fabrice

Gustave Roussy Institute, Villejuif, France
Batistatou Anna

University of Ioannina, Ioannina, Greece
Cognetti Francesco

Istituto Nazionale Tumori Regina Elena, Rome, Italy
Danesi Romano

University of Pisa, Pisa, Italy
Gligorov Joseph

Hospital Tenon Ap-Hp, Paris, France
Harbeck Nadia

Breast Center, LMU University Hospital, Munich, Germany
Markopoulos Christos

Medical School, National University of Athens, Athens, Greece
Martin Miguel

Hospital General Universitario Gregorio Marañón, Madrid, Spain
Masetti Riccardo

Università Cattolica di Roma, Rome, Italy
Nitz Ulrike

Johanniter Hospital Bethesda, Mönchengladbach, Germany
Penault-Llorca Frederique

Jean Perrin Center, Clermont-Ferrand, France
Pruneri Giancarlo

IRCCS National Cancer Institute, Milan, Italy
Pujol Pascal

Centre Hospitalier Universitaire de Montpellier, Montpellier, France
Senkus Elzbieta

Medical University of Gdansk, Gdansk, Poland
Varga Zsuzsanna

University Hospital Zurich, Zurich, Switzerland
Verrill Mark

Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Zambon Marzia

EUROPA DONNA - The European Breast Cancer Coalition, Milan, Italy
Login for the Online Course

Under the auspices of

EUROPA DONNA

European Society of Pathology

EUSOMA